homejournalsoncology-nurseOncology Nursing News® is published 6 print issues every year. This page features the content from those publications.February 2022Volume: 16Issue: 1December 2021Volume: 15Issue: 6October 2021Volume: 15Issue: 5August 2021Volume: 15Issue: 4June 2021Volume: 15Issue: 3April 2021Volume: 15Issue: 02February 2021Volume: 15Issue: 1February 2020Volume: 1Issue: 1April 2020Volume:…
An expert discussed a screening tool that she and her colleagues used to connect patients with cancer to palliative care services in a more effective…
Lutetium Lu 177 dotatate was approved by the FDA for children aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone…
Nogapendekin alfa inbakicept-pmln has been approved for use with BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or…
All patients treated with CAR T-cell products are recommended to be monitored life-long for the risk of secondary malignancy, according to the FDA.
Patients with head and neck squamous cell carcinoma treated with atezolizumab after definitive local therapy did not see improvements in survival outcomes.
Fast track designation has been granted by the FDA to PT217 for extensive stage small cell lung cancer with disease progression.
Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death…
Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased…
Zanubrutinib to treat chronic lymphocytic leukemia or small lymphocytic lymphoma was linked with fewer cardiac adverse effects compared with ibrutinib and acalabrutinib.
